In the Margins

Sequoia Fund manager details Valeant experience

March 1, 2016

By Barron's

In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.

 

 

Most Read

Viewpoints
Op-Ed: The Must Know of D&O

For most, D&O insurance is as exciting a topic as tooth enamel. In fact, prevailing views about the two (insurance and enamel) are likely quite similar: ...